Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02803593 · ClinicalTrials.gov registry record · NA

To Enhance Breast Cancer Survivorship of Asian Americans

A NA study of Breast Cancer, sponsored by Emory University.

Completed
Registry status
NA
Development phase
199
Enrollment target
2
Study locations

NCT02803593 is a NA study of Breast Cancer that has completed, run by Emory University. The registered enrollment target is 199 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02803593, a NA study of Breast Cancer, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
199 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.

Conditions Studied

Interventions

  • BEHAVIORAL Technology-based information and coaching/support program
  • BEHAVIORAL American Cancer Society information on breast cancer

Study Locations (2)

Georgia

  • Emory University Hospital - Atlanta

North Carolina

  • Duke University, School of Nursing - Durham

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 2016-06
Est. Completion 2021-06-09
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT02803593

The ClinicalTrials.gov registry entry for NCT02803593 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Technology-based information and coaching/support program is the first listed.

NCT02803593 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02803593 about?

NCT02803593 is a clinical study titled "To Enhance Breast Cancer Survivorship of Asian Americans". The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.

What is the current status of trial NCT02803593?

This trial is currently completed. It is a NA study. The enrollment target is 199 participants. The study started on 2016-06. Estimated completion is 2021-06-09.

What conditions does trial NCT02803593 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02803593?

The interventions under investigation include: Technology-based information and coaching/support program (BEHAVIORAL), American Cancer Society information on breast cancer (BEHAVIORAL).

Who is sponsoring clinical trial NCT02803593?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02803593 being conducted?

This trial has 2 study locations across Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.